Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intel Corporation    INTC


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Dow, S&P futures gain on hopes of progress in stimulus talks

10/23/2020 | 06:45am EST

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)

* Futures: Dow up 0.3%, S&P up 0.2%, Nasdaq down 0.1%

Oct 23 (Reuters) - Futures tracking the S&P 500 and the Dow edged higher on Friday, as investors anticipated progress in bipartisan talks over the next coronavirus aid bill ahead of the Nov. 3 presidential election.

U.S. House Speaker Nancy Pelosi said on Thursday there was progress in negotiations with the White House, but Senate Republicans remained skeptical of a possible deal costing trillions of dollars.

Uncertainly over the timeline of the relief legislature has been weighing on Wall Street's major indexes, which were set to end a choppy week slightly lower.

Meanwhile, a record 47 million Americans cast ballots, eclipsing total early voting from the 2016 election. President Donald Trump and Democratic rival Joe Biden debated on Thursday for the last time to persuade the few remaining undecided voters 12 days before their contest.

At 06:24 a.m. ET, Dow E-minis were up 0.31% at 28,352 points, S&P 500 E-minis rose 0.17% to 3,455 points. Nasdaq 100 E-minis fell 0.07% to 11,643 points.

Third-quarter earnings season chugged along with 126 S&P firms having reported so far. About 84% of them have topped quarterly profit estimates, according to Refinitiv data.

Chipmaker Intel Corp tumbled nearly 10% in premarket trading after it reported that margins fell as consumers bought cheaper laptops and pandemic-stricken businesses and governments clamped down on data center spending.

Gilead Sciences Inc jumped 5.8% as its antiviral drug remdesivir became the first and only drug approved for treating patients hospitalized with COVID-19 in the United States.

Apple Inc edged 0.3% higher as two of its latest iPhone 12 models went on sale in China on Friday. (Reporting by Medha Singh in Bengaluru; Editing by Arun Koyyur)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
APPLE INC. 0.48% 116.59 Delayed Quote.58.05%
DJ INDUSTRIAL 0.13% 29910.37 Delayed Quote.4.67%
GILEAD SCIENCES, INC. 0.89% 60.03 Delayed Quote.-7.62%
INTEL CORPORATION 0.85% 47.45 Delayed Quote.-21.39%
NASDAQ 100 0.87% 12258.211779 Delayed Quote.40.37%
NASDAQ COMP. 0.92% 12205.846315 Delayed Quote.34.79%
S&P 500 0.24% 3638.35 Delayed Quote.12.62%
11/27INTEL : Senegal's UVS uses Atos' BullSequana Intel-based supercomputer to evalua..
11/23BOB SWAN : Open Letter to President-elect Biden
11/20Luminar to supply lidar sensors for Mobileye's self-driving fleet
11/20INTEL : NUC Kit Lays a Solid Whitebook Laptop Foundation
11/18Nvidia Benefits from Sustained Pandemic-Era Remote Work, Videogaming Demand -..
11/18NVIDIA : shares dip on predicted decline in data center sales
11/18Nvidia Benefits from Sustained Pandemic-Era Remote Work, Videogaming Demand -..
11/18Phoenix okays development deal with TSMC for $12 billion chip factory
11/18Phoenix okays development deal with TSMC for $12 bln chip factory
11/18Nvidia Benefits from Sustained Pandemic-Era Remote Work, Videogaming Demand
More news
Financials (USD)
Sales 2020 75 333 M - -
Net income 2020 19 309 M - -
Net Debt 2020 21 979 M - -
P/E ratio 2020 10,4x
Yield 2020 2,80%
Capitalization 194 B 194 B -
EV / Sales 2020 2,87x
EV / Sales 2021 2,93x
Nbr of Employees 110 800
Free-Float 99,9%
Duration : Period :
Intel Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTEL CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 43
Average target price 54,11 $
Last Close Price 47,45 $
Spread / Highest target 111%
Spread / Average Target 14,0%
Spread / Lowest Target -24,1%
EPS Revisions
Robert Holmes Swan Chief Executive Officer & Director
Omar S. Ishrak Independent Chairman
Ann-Marie Holmes Vice President-Operations & Manufacturing
George S. Davis Chief Financial Officer & Executive Vice President
Daniel J. McKeon Vice President-Information Technology Group